Activin and Inhibin

ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRAS G12C nucleotide state in living cellsForm:SolidIC50&amp: Target:KRAS(G12C).

ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRAS G12C nucleotide state in living cellsForm:SolidIC50&amp: Target:KRAS(G12C).

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.In VitroKRAS G12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.In VitroKRAS G12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.In VitroKRAS G12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.In VitroKRAS G12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.In VitroKRAS G12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.In VitroKRAS G12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in

ART558 is a nanomolar potent, selective, low molecular weight, allosteric DNA polymerase activity of Polθ inhibitor ( IC 50 =7.9 nM). ART558 can be used for the research of cancerIn VitroART558 (0~10 μM: 7 days: BRCA2 wild-type or BRCA2 ‒/‒ cells)

ART558 is a nanomolar potent, selective, low molecular weight, allosteric DNA polymerase activity of Polθ inhibitor ( IC 50 =7.9 nM). ART558 can be used for the research of cancerIn VitroART558 (0~10 μM: 7 days: BRCA2 wild-type or BRCA2 ‒/‒ cells)

ART558 is a nanomolar potent, selective, low molecular weight, allosteric DNA polymerase activity of Polθ inhibitor ( IC 50 =7.9 nM). ART558 can be used for the research of cancerIn VitroART558 (0~10 μM: 7 days: BRCA2 wild-type or BRCA2 ‒/‒ cells)

ART812 is an orally active DNA polymerase Polθ inhibitor with an IC 50 value of 7.6 nM. ART812 has an IC 50 value of 240 nM for cell based microhomology-mediated end joining (MMEJ)In VitroART812 (0-40 μM) elicits Polθ inhibitor sensitivity in